Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Vaccines | 28 | 2024 | 222 | 7.760 |
Why?
|
Vaccination | 48 | 2024 | 674 | 6.600 |
Why?
|
Immunization Schedule | 14 | 2022 | 133 | 3.800 |
Why?
|
Drug Overdose | 9 | 2023 | 57 | 3.260 |
Why?
|
Influenza Vaccines | 21 | 2024 | 290 | 2.920 |
Why?
|
Infant | 50 | 2023 | 1245 | 2.920 |
Why?
|
Opioid-Related Disorders | 6 | 2023 | 168 | 2.630 |
Why?
|
Analgesics, Opioid | 11 | 2023 | 241 | 2.520 |
Why?
|
Social Media | 4 | 2021 | 12 | 2.510 |
Why?
|
Humans | 121 | 2024 | 18430 | 2.450 |
Why?
|
Parents | 10 | 2021 | 309 | 2.370 |
Why?
|
Child, Preschool | 45 | 2023 | 1478 | 2.250 |
Why?
|
Influenza, Human | 14 | 2024 | 282 | 1.950 |
Why?
|
Patient Acceptance of Health Care | 6 | 2024 | 407 | 1.790 |
Why?
|
Health Knowledge, Attitudes, Practice | 12 | 2021 | 392 | 1.680 |
Why?
|
Female | 75 | 2024 | 13136 | 1.650 |
Why?
|
Male | 63 | 2024 | 10440 | 1.590 |
Why?
|
Vaccines, Inactivated | 9 | 2020 | 70 | 1.490 |
Why?
|
Child | 37 | 2022 | 2571 | 1.420 |
Why?
|
Aluminum | 3 | 2022 | 14 | 1.380 |
Why?
|
Diabetes Mellitus, Type 1 | 2 | 2021 | 124 | 1.360 |
Why?
|
United States | 44 | 2024 | 4164 | 1.330 |
Why?
|
Cohort Studies | 30 | 2024 | 2672 | 1.320 |
Why?
|
Retrospective Studies | 28 | 2024 | 2550 | 1.310 |
Why?
|
Pregnancy Complications, Infectious | 7 | 2024 | 142 | 1.300 |
Why?
|
Internet | 4 | 2020 | 243 | 1.300 |
Why?
|
Consumer Health Information | 3 | 2020 | 14 | 1.280 |
Why?
|
Mothers | 2 | 2020 | 110 | 1.270 |
Why?
|
Treatment Refusal | 6 | 2015 | 38 | 1.230 |
Why?
|
Diphtheria-Tetanus-acellular Pertussis Vaccines | 7 | 2020 | 95 | 1.190 |
Why?
|
Rotavirus Vaccines | 5 | 2020 | 50 | 1.190 |
Why?
|
Patient Safety | 2 | 2020 | 41 | 1.180 |
Why?
|
Models, Statistical | 4 | 2014 | 185 | 1.160 |
Why?
|
Colorado | 12 | 2024 | 211 | 1.120 |
Why?
|
Patient Education as Topic | 4 | 2019 | 214 | 1.120 |
Why?
|
Adverse Drug Reaction Reporting Systems | 5 | 2016 | 101 | 1.090 |
Why?
|
Incidence | 17 | 2022 | 1314 | 1.020 |
Why?
|
Naloxone | 5 | 2020 | 19 | 0.990 |
Why?
|
Adolescent | 35 | 2021 | 3798 | 0.990 |
Why?
|
Vaccination Coverage | 6 | 2024 | 45 | 0.990 |
Why?
|
Case-Control Studies | 20 | 2020 | 1173 | 0.950 |
Why?
|
Adult | 36 | 2024 | 7910 | 0.940 |
Why?
|
Measles-Mumps-Rubella Vaccine | 7 | 2021 | 67 | 0.930 |
Why?
|
Whooping Cough | 4 | 2013 | 75 | 0.920 |
Why?
|
Antibodies, Viral | 1 | 2024 | 65 | 0.920 |
Why?
|
Statistics as Topic | 2 | 2013 | 66 | 0.850 |
Why?
|
Risk Assessment | 11 | 2020 | 1143 | 0.850 |
Why?
|
Narcotic Antagonists | 3 | 2020 | 16 | 0.840 |
Why?
|
Measles | 2 | 2021 | 26 | 0.840 |
Why?
|
Antigens | 2 | 2021 | 7 | 0.820 |
Why?
|
Safety | 4 | 2016 | 45 | 0.810 |
Why?
|
Decision Making | 4 | 2019 | 204 | 0.810 |
Why?
|
Vaccines, Attenuated | 4 | 2020 | 47 | 0.800 |
Why?
|
Bias | 3 | 2019 | 111 | 0.760 |
Why?
|
Product Surveillance, Postmarketing | 7 | 2022 | 110 | 0.760 |
Why?
|
Text Messaging | 1 | 2021 | 31 | 0.750 |
Why?
|
Reminder Systems | 1 | 2021 | 94 | 0.720 |
Why?
|
Pregnancy | 15 | 2024 | 1516 | 0.720 |
Why?
|
Chickenpox Vaccine | 5 | 2021 | 101 | 0.710 |
Why?
|
Communicable Diseases | 1 | 2020 | 15 | 0.700 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 4 | 2020 | 116 | 0.700 |
Why?
|
Influenza A Virus, H1N1 Subtype | 4 | 2017 | 56 | 0.670 |
Why?
|
Disease Outbreaks | 3 | 2015 | 39 | 0.650 |
Why?
|
Naltrexone | 1 | 2018 | 17 | 0.640 |
Why?
|
Pneumococcal Vaccines | 3 | 2020 | 80 | 0.630 |
Why?
|
Infection | 1 | 2018 | 17 | 0.620 |
Why?
|
Infant, Newborn | 13 | 2024 | 872 | 0.610 |
Why?
|
Gastrointestinal Diseases | 2 | 2018 | 28 | 0.600 |
Why?
|
Electronic Health Records | 5 | 2019 | 747 | 0.600 |
Why?
|
Abortion, Spontaneous | 4 | 2021 | 52 | 0.600 |
Why?
|
Patient Compliance | 2 | 2019 | 318 | 0.590 |
Why?
|
Young Adult | 20 | 2024 | 2518 | 0.590 |
Why?
|
Information Dissemination | 1 | 2017 | 57 | 0.590 |
Why?
|
Professional-Family Relations | 2 | 2015 | 50 | 0.560 |
Why?
|
Middle Aged | 22 | 2024 | 8284 | 0.540 |
Why?
|
Databases, Pharmaceutical | 1 | 2016 | 6 | 0.540 |
Why?
|
Environmental Exposure | 2 | 2015 | 115 | 0.540 |
Why?
|
Odds Ratio | 5 | 2019 | 701 | 0.530 |
Why?
|
Adjuvants, Immunologic | 1 | 2015 | 15 | 0.520 |
Why?
|
Prescription Drug Diversion | 1 | 2015 | 3 | 0.500 |
Why?
|
Hospitalization | 7 | 2020 | 847 | 0.490 |
Why?
|
Housing | 1 | 2015 | 40 | 0.490 |
Why?
|
Algorithms | 2 | 2014 | 241 | 0.470 |
Why?
|
Health Education | 1 | 2014 | 115 | 0.460 |
Why?
|
Biometry | 1 | 2014 | 13 | 0.460 |
Why?
|
Sentinel Surveillance | 1 | 2013 | 14 | 0.460 |
Why?
|
Selection Bias | 1 | 2013 | 24 | 0.460 |
Why?
|
Managed Care Programs | 2 | 2013 | 347 | 0.460 |
Why?
|
Trust | 1 | 2013 | 31 | 0.450 |
Why?
|
Confidence Intervals | 5 | 2021 | 253 | 0.440 |
Why?
|
Biostatistics | 1 | 2012 | 10 | 0.410 |
Why?
|
Purpura, Thrombocytopenic, Idiopathic | 2 | 2012 | 5 | 0.410 |
Why?
|
Health Services | 1 | 2013 | 117 | 0.400 |
Why?
|
Models, Theoretical | 4 | 2020 | 76 | 0.400 |
Why?
|
Intussusception | 3 | 2014 | 16 | 0.390 |
Why?
|
Reproducibility of Results | 3 | 2020 | 399 | 0.390 |
Why?
|
Public Health Surveillance | 3 | 2020 | 45 | 0.390 |
Why?
|
Aged | 13 | 2024 | 6417 | 0.390 |
Why?
|
Time Factors | 8 | 2013 | 1136 | 0.380 |
Why?
|
Immunization | 4 | 2024 | 80 | 0.380 |
Why?
|
Pneumonia, Pneumococcal | 1 | 2010 | 14 | 0.370 |
Why?
|
Epidemiologic Research Design | 1 | 2010 | 24 | 0.370 |
Why?
|
Logistic Models | 6 | 2020 | 962 | 0.370 |
Why?
|
Proportional Hazards Models | 4 | 2021 | 743 | 0.360 |
Why?
|
Pandemics | 5 | 2024 | 292 | 0.360 |
Why?
|
Prescriptions | 2 | 2020 | 28 | 0.360 |
Why?
|
Risk | 11 | 2021 | 552 | 0.350 |
Why?
|
Clinical Trials as Topic | 1 | 2010 | 133 | 0.350 |
Why?
|
Focus Groups | 3 | 2015 | 154 | 0.350 |
Why?
|
Chickenpox | 1 | 2010 | 38 | 0.340 |
Why?
|
Pertussis Vaccine | 1 | 2009 | 17 | 0.340 |
Why?
|
Qualitative Research | 4 | 2020 | 272 | 0.330 |
Why?
|
Mortality | 3 | 2021 | 123 | 0.330 |
Why?
|
Computer Simulation | 4 | 2013 | 85 | 0.330 |
Why?
|
Age Factors | 6 | 2020 | 965 | 0.320 |
Why?
|
Population Surveillance | 6 | 2013 | 271 | 0.320 |
Why?
|
Thrombocytopenia | 2 | 2022 | 15 | 0.310 |
Why?
|
Research Design | 4 | 2024 | 402 | 0.310 |
Why?
|
Immunization Programs | 4 | 2022 | 68 | 0.300 |
Why?
|
Epidemiologic Methods | 3 | 2019 | 87 | 0.290 |
Why?
|
Alcoholism | 5 | 2012 | 350 | 0.290 |
Why?
|
Chronic Pain | 2 | 2020 | 128 | 0.280 |
Why?
|
Database Management Systems | 2 | 2020 | 15 | 0.280 |
Why?
|
Risk Factors | 12 | 2020 | 3449 | 0.280 |
Why?
|
Centers for Disease Control and Prevention (U.S.) | 3 | 2016 | 33 | 0.280 |
Why?
|
Cross-Sectional Studies | 5 | 2024 | 1360 | 0.260 |
Why?
|
Heroin Dependence | 2 | 2020 | 6 | 0.250 |
Why?
|
Health Services Research | 1 | 2006 | 264 | 0.240 |
Why?
|
Immunity, Humoral | 1 | 2024 | 3 | 0.240 |
Why?
|
Multivariate Analysis | 5 | 2017 | 598 | 0.240 |
Why?
|
Alcohol Drinking | 3 | 2002 | 375 | 0.240 |
Why?
|
Seasons | 4 | 2024 | 105 | 0.240 |
Why?
|
RNA, Viral | 1 | 2024 | 64 | 0.240 |
Why?
|
World Health Organization | 3 | 2002 | 15 | 0.240 |
Why?
|
Health Behavior | 2 | 2019 | 374 | 0.230 |
Why?
|
Stillbirth | 2 | 2021 | 30 | 0.230 |
Why?
|
Seizures | 2 | 2014 | 30 | 0.230 |
Why?
|
Predictive Value of Tests | 2 | 2019 | 365 | 0.230 |
Why?
|
Premature Birth | 2 | 2024 | 138 | 0.220 |
Why?
|
Gestational Age | 2 | 2021 | 119 | 0.220 |
Why?
|
Monkeypox | 1 | 2022 | 1 | 0.220 |
Why?
|
Smallpox Vaccine | 1 | 2022 | 6 | 0.220 |
Why?
|
Substance-Related Disorders | 3 | 2020 | 439 | 0.220 |
Why?
|
Morphine Derivatives | 1 | 2022 | 3 | 0.210 |
Why?
|
Surveys and Questionnaires | 4 | 2020 | 1389 | 0.210 |
Why?
|
Drug Prescriptions | 2 | 2015 | 157 | 0.210 |
Why?
|
Eczema | 1 | 2022 | 7 | 0.210 |
Why?
|
Pericarditis | 1 | 2022 | 14 | 0.210 |
Why?
|
Cataplexy | 1 | 2022 | 5 | 0.210 |
Why?
|
Narcolepsy | 1 | 2022 | 6 | 0.210 |
Why?
|
Myocarditis | 1 | 2022 | 18 | 0.210 |
Why?
|
Data Interpretation, Statistical | 2 | 2021 | 83 | 0.210 |
Why?
|
Bell Palsy | 1 | 2022 | 17 | 0.200 |
Why?
|
Guillain-Barre Syndrome | 1 | 2022 | 19 | 0.200 |
Why?
|
Databases, Factual | 2 | 2014 | 327 | 0.200 |
Why?
|
Diphtheria-Tetanus-Pertussis Vaccine | 2 | 2014 | 30 | 0.200 |
Why?
|
Anemia, Sickle Cell | 2 | 2011 | 9 | 0.200 |
Why?
|
Practice Patterns, Physicians' | 4 | 2021 | 350 | 0.200 |
Why?
|
Maternal Age | 1 | 2021 | 80 | 0.200 |
Why?
|
Medical Informatics | 2 | 2019 | 45 | 0.190 |
Why?
|
Sex Factors | 3 | 2021 | 661 | 0.190 |
Why?
|
Follow-Up Studies | 3 | 2020 | 1269 | 0.190 |
Why?
|
HIV Infections | 2 | 2024 | 695 | 0.190 |
Why?
|
Heroin | 1 | 2020 | 5 | 0.180 |
Why?
|
Haemophilus Vaccines | 1 | 2020 | 25 | 0.180 |
Why?
|
Telemedicine | 1 | 2024 | 184 | 0.180 |
Why?
|
Sensitivity and Specificity | 2 | 2019 | 321 | 0.180 |
Why?
|
Withholding Treatment | 1 | 2020 | 26 | 0.180 |
Why?
|
Motivation | 1 | 2021 | 137 | 0.180 |
Why?
|
London | 1 | 2020 | 7 | 0.180 |
Why?
|
Disease Susceptibility | 1 | 2020 | 46 | 0.180 |
Why?
|
Congresses as Topic | 1 | 2020 | 13 | 0.180 |
Why?
|
Pilot Projects | 1 | 2020 | 237 | 0.170 |
Why?
|
Bacterial Vaccines | 2 | 2023 | 17 | 0.170 |
Why?
|
Coronavirus Infections | 1 | 2020 | 50 | 0.170 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 57 | 0.170 |
Why?
|
California | 2 | 2024 | 2365 | 0.170 |
Why?
|
Papillomavirus Vaccines | 1 | 2021 | 118 | 0.170 |
Why?
|
Pregnant Women | 1 | 2020 | 44 | 0.170 |
Why?
|
Insurance, Health | 1 | 2021 | 217 | 0.170 |
Why?
|
Vaccination Refusal | 1 | 2019 | 10 | 0.170 |
Why?
|
Asthma | 1 | 2022 | 390 | 0.170 |
Why?
|
Parenting | 1 | 2019 | 29 | 0.170 |
Why?
|
Papillomavirus Infections | 1 | 2021 | 136 | 0.170 |
Why?
|
Cause of Death | 3 | 2018 | 185 | 0.160 |
Why?
|
Delayed-Action Preparations | 1 | 2018 | 6 | 0.160 |
Why?
|
Delivery of Health Care, Integrated | 3 | 2021 | 567 | 0.160 |
Why?
|
Croup | 1 | 2018 | 4 | 0.160 |
Why?
|
Otitis Media | 1 | 2018 | 21 | 0.150 |
Why?
|
Infant Mortality | 1 | 2018 | 22 | 0.150 |
Why?
|
Analysis of Variance | 4 | 2008 | 167 | 0.150 |
Why?
|
Attitude to Health | 1 | 2019 | 177 | 0.150 |
Why?
|
Chronic Disease | 2 | 2013 | 468 | 0.150 |
Why?
|
Infectious Disease Transmission, Vertical | 1 | 2017 | 22 | 0.150 |
Why?
|
Respiratory Tract Infections | 1 | 2018 | 54 | 0.150 |
Why?
|
Attitude of Health Personnel | 2 | 2016 | 226 | 0.150 |
Why?
|
Pneumonia | 1 | 2017 | 56 | 0.150 |
Why?
|
Poisson Distribution | 3 | 2014 | 94 | 0.140 |
Why?
|
Measles Vaccine | 1 | 2017 | 21 | 0.140 |
Why?
|
Venous Thromboembolism | 1 | 2017 | 52 | 0.140 |
Why?
|
Intensive Care Units | 1 | 2017 | 106 | 0.140 |
Why?
|
Fever | 1 | 2017 | 60 | 0.140 |
Why?
|
Cluster Analysis | 1 | 2017 | 96 | 0.140 |
Why?
|
Acute Disease | 2 | 2008 | 144 | 0.140 |
Why?
|
Socioeconomic Factors | 5 | 2019 | 673 | 0.140 |
Why?
|
Immunization, Secondary | 3 | 2014 | 64 | 0.140 |
Why?
|
Sex Distribution | 3 | 2017 | 198 | 0.130 |
Why?
|
Ambulatory Care | 2 | 2018 | 266 | 0.130 |
Why?
|
Age Distribution | 3 | 2017 | 261 | 0.130 |
Why?
|
General Practice | 1 | 2015 | 6 | 0.130 |
Why?
|
Clinical Competence | 1 | 2015 | 108 | 0.130 |
Why?
|
Seizures, Febrile | 2 | 2013 | 47 | 0.130 |
Why?
|
User-Computer Interface | 1 | 2014 | 28 | 0.120 |
Why?
|
Physicians, Primary Care | 1 | 2015 | 74 | 0.120 |
Why?
|
Heptavalent Pneumococcal Conjugate Vaccine | 2 | 2013 | 22 | 0.120 |
Why?
|
Aged, 80 and over | 6 | 2017 | 2003 | 0.120 |
Why?
|
Community Health Services | 1 | 2015 | 86 | 0.120 |
Why?
|
Program Development | 1 | 2014 | 81 | 0.120 |
Why?
|
Needle Sharing | 2 | 2005 | 2 | 0.120 |
Why?
|
Prisoners | 1 | 2015 | 58 | 0.120 |
Why?
|
Poliovirus Vaccine, Inactivated | 1 | 2014 | 21 | 0.120 |
Why?
|
Viral Vaccines | 1 | 2014 | 15 | 0.120 |
Why?
|
Evidence-Based Medicine | 1 | 2015 | 195 | 0.120 |
Why?
|
Substance Abuse, Intravenous | 2 | 2005 | 32 | 0.110 |
Why?
|
Communication | 1 | 2015 | 202 | 0.110 |
Why?
|
Mass Vaccination | 1 | 2013 | 22 | 0.110 |
Why?
|
Prehypertension | 1 | 2013 | 22 | 0.110 |
Why?
|
Hepatitis C | 2 | 2005 | 65 | 0.110 |
Why?
|
Drug Utilization | 1 | 2013 | 134 | 0.110 |
Why?
|
Genes, MHC Class II | 1 | 2012 | 2 | 0.110 |
Why?
|
Diphtheria | 1 | 2012 | 14 | 0.110 |
Why?
|
Tetanus | 1 | 2012 | 18 | 0.110 |
Why?
|
Prescription Drugs | 1 | 2013 | 33 | 0.100 |
Why?
|
Primary Health Care | 2 | 2016 | 848 | 0.100 |
Why?
|
Adenylyl Cyclases | 2 | 2002 | 2 | 0.100 |
Why?
|
Outcome and Process Assessment (Health Care) | 1 | 2012 | 110 | 0.100 |
Why?
|
Comparative Effectiveness Research | 1 | 2012 | 77 | 0.100 |
Why?
|
Prisons | 1 | 2012 | 32 | 0.100 |
Why?
|
Antiviral Agents | 1 | 2012 | 95 | 0.100 |
Why?
|
Blood Pressure | 1 | 2013 | 310 | 0.100 |
Why?
|
Guideline Adherence | 1 | 2012 | 162 | 0.090 |
Why?
|
Quality Assurance, Health Care | 1 | 2012 | 188 | 0.090 |
Why?
|
Community Health Centers | 1 | 2012 | 112 | 0.090 |
Why?
|
Autistic Disorder | 1 | 2011 | 105 | 0.090 |
Why?
|
Multicenter Studies as Topic | 2 | 2008 | 91 | 0.090 |
Why?
|
Anemia, Hemolytic | 1 | 2009 | 2 | 0.090 |
Why?
|
Linear Models | 2 | 2008 | 243 | 0.080 |
Why?
|
Severity of Illness Index | 2 | 2008 | 476 | 0.080 |
Why?
|
Hepatitis B Vaccines | 1 | 2009 | 46 | 0.080 |
Why?
|
Brain Ischemia | 1 | 2009 | 37 | 0.080 |
Why?
|
Registries | 2 | 2008 | 490 | 0.080 |
Why?
|
Drug Evaluation | 1 | 2008 | 7 | 0.080 |
Why?
|
Hypertension | 1 | 2013 | 524 | 0.080 |
Why?
|
Health Surveys | 1 | 2009 | 269 | 0.080 |
Why?
|
Splenectomy | 1 | 2008 | 2 | 0.080 |
Why?
|
Purpura, Thrombocytopenic | 1 | 2008 | 2 | 0.080 |
Why?
|
Platelet Count | 1 | 2008 | 9 | 0.080 |
Why?
|
Communicable Disease Control | 1 | 2008 | 19 | 0.080 |
Why?
|
Prospective Studies | 3 | 2014 | 1314 | 0.080 |
Why?
|
Mass Screening | 1 | 2013 | 690 | 0.070 |
Why?
|
Survival Analysis | 1 | 2008 | 226 | 0.070 |
Why?
|
Regression Analysis | 4 | 2015 | 319 | 0.070 |
Why?
|
Disease Progression | 1 | 2008 | 271 | 0.070 |
Why?
|
Prognosis | 1 | 2008 | 624 | 0.070 |
Why?
|
Stroke | 1 | 2009 | 311 | 0.070 |
Why?
|
Confounding Factors (Epidemiology) | 1 | 2006 | 99 | 0.070 |
Why?
|
Hepatitis B | 1 | 2005 | 43 | 0.060 |
Why?
|
Health Personnel | 2 | 2015 | 126 | 0.060 |
Why?
|
Family Characteristics | 1 | 2023 | 54 | 0.060 |
Why?
|
Pregnancy Outcome | 1 | 2024 | 159 | 0.050 |
Why?
|
Cooperative Behavior | 2 | 2014 | 102 | 0.050 |
Why?
|
Vaccines, Combined | 2 | 2014 | 91 | 0.050 |
Why?
|
Monoamine Oxidase | 1 | 2002 | 1 | 0.050 |
Why?
|
Blood Platelets | 1 | 2002 | 2 | 0.050 |
Why?
|
Genetic Markers | 1 | 2002 | 28 | 0.050 |
Why?
|
Prevalence | 2 | 2021 | 911 | 0.050 |
Why?
|
RNA, Messenger | 1 | 2022 | 80 | 0.050 |
Why?
|
Chi-Square Distribution | 1 | 2002 | 160 | 0.050 |
Why?
|
Vaccines, Synthetic | 1 | 2022 | 43 | 0.050 |
Why?
|
Body Water | 1 | 2001 | 3 | 0.050 |
Why?
|
Transferrin | 1 | 2001 | 5 | 0.050 |
Why?
|
Hypoxanthine Phosphoribosyltransferase | 1 | 2001 | 1 | 0.050 |
Why?
|
Radon | 1 | 2001 | 3 | 0.050 |
Why?
|
Bacterial Capsules | 1 | 2020 | 7 | 0.050 |
Why?
|
Policy | 1 | 2021 | 19 | 0.050 |
Why?
|
Health Facilities | 1 | 2020 | 18 | 0.050 |
Why?
|
Mutation | 1 | 2001 | 132 | 0.040 |
Why?
|
History, 21st Century | 1 | 2019 | 25 | 0.040 |
Why?
|
Health Status Disparities | 1 | 2021 | 153 | 0.040 |
Why?
|
Smoking | 1 | 2002 | 494 | 0.040 |
Why?
|
Continental Population Groups | 1 | 2021 | 315 | 0.040 |
Why?
|
Psychometrics | 1 | 2019 | 124 | 0.040 |
Why?
|
Respiratory Tract Diseases | 1 | 2018 | 25 | 0.040 |
Why?
|
Ethnic Groups | 1 | 2021 | 501 | 0.040 |
Why?
|
Venous Thrombosis | 1 | 2017 | 21 | 0.040 |
Why?
|
International Classification of Diseases | 1 | 2017 | 87 | 0.040 |
Why?
|
Pulmonary Embolism | 1 | 2017 | 44 | 0.040 |
Why?
|
Outpatients | 1 | 2018 | 111 | 0.040 |
Why?
|
Family Health | 1 | 2017 | 49 | 0.040 |
Why?
|
Body Mass Index | 1 | 2001 | 974 | 0.030 |
Why?
|
Biomarkers | 3 | 2002 | 308 | 0.030 |
Why?
|
Neoplasms | 1 | 2001 | 457 | 0.030 |
Why?
|
Comorbidity | 1 | 2017 | 619 | 0.030 |
Why?
|
Contraindications | 1 | 2014 | 15 | 0.030 |
Why?
|
Emergency Medical Services | 1 | 2013 | 47 | 0.030 |
Why?
|
Anaphylaxis | 1 | 2013 | 15 | 0.030 |
Why?
|
Mucocutaneous Lymph Node Syndrome | 1 | 2013 | 19 | 0.030 |
Why?
|
Fetal Mortality | 1 | 2013 | 2 | 0.030 |
Why?
|
Fetal Death | 1 | 2013 | 10 | 0.030 |
Why?
|
Vaccines, Acellular | 1 | 2012 | 12 | 0.030 |
Why?
|
Vaccines, Conjugate | 1 | 2013 | 66 | 0.030 |
Why?
|
Ultrasonography | 1 | 2013 | 36 | 0.030 |
Why?
|
Off-Label Use | 1 | 2012 | 14 | 0.030 |
Why?
|
Health Services Accessibility | 1 | 2015 | 320 | 0.030 |
Why?
|
Hepatitis A Vaccines | 1 | 2012 | 14 | 0.030 |
Why?
|
Rotavirus Infections | 1 | 2012 | 31 | 0.030 |
Why?
|
Monitoring, Immunologic | 1 | 2011 | 4 | 0.020 |
Why?
|
Safety Management | 1 | 2011 | 15 | 0.020 |
Why?
|
Family | 1 | 2012 | 120 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 1 | 2012 | 414 | 0.020 |
Why?
|
Mental Health | 1 | 2012 | 168 | 0.020 |
Why?
|
Social Support | 1 | 2012 | 214 | 0.020 |
Why?
|
Suicide | 1 | 2012 | 126 | 0.020 |
Why?
|
Patient-Centered Care | 1 | 2012 | 228 | 0.020 |
Why?
|
Emergency Service, Hospital | 1 | 2012 | 382 | 0.020 |
Why?
|
Syringes | 1 | 2005 | 1 | 0.020 |
Why?
|
Cocaine-Related Disorders | 1 | 2005 | 5 | 0.020 |
Why?
|
Amphetamine-Related Disorders | 1 | 2005 | 4 | 0.020 |
Why?
|
Social Identification | 1 | 2005 | 8 | 0.020 |
Why?
|
Methamphetamine | 1 | 2005 | 3 | 0.020 |
Why?
|
Cross-Over Studies | 1 | 2004 | 45 | 0.020 |
Why?
|
Medical Record Linkage | 1 | 2004 | 44 | 0.020 |
Why?
|
Social Environment | 1 | 2005 | 90 | 0.020 |
Why?
|
Equipment Contamination | 1 | 2003 | 1 | 0.010 |
Why?
|
Illinois | 1 | 2003 | 8 | 0.010 |
Why?
|
Affinity Labels | 1 | 2002 | 1 | 0.010 |
Why?
|
Enzyme Activation | 1 | 2002 | 6 | 0.010 |
Why?
|
Protein Binding | 1 | 2002 | 9 | 0.010 |
Why?
|
Statistics, Nonparametric | 1 | 2002 | 51 | 0.010 |
Why?
|
Health Maintenance Organizations | 1 | 2004 | 479 | 0.010 |
Why?
|
Marijuana Abuse | 1 | 2002 | 41 | 0.010 |
Why?
|
gamma-Glutamyltransferase | 1 | 2001 | 3 | 0.010 |
Why?
|
Aspartate Aminotransferases | 1 | 2001 | 14 | 0.010 |
Why?
|
Multifactorial Inheritance | 1 | 2001 | 20 | 0.010 |
Why?
|
Causality | 1 | 2001 | 43 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2003 | 724 | 0.010 |
Why?
|